Author:
Montal Robert,Andreu-Oller Carmen,Bassaganyas Laia,Esteban-Fabró Roger,Moran Sebastián,Montironi Carla,Moeini Agrin,Pinyol Roser,Peix Judit,Cabellos Laia,Villanueva Augusto,Sia Daniela,Mazzaferro Vincenzo,Esteller Manel,Llovet Josep M.
Publisher
Springer Science and Business Media LLC
Reference13 articles.
1. Llovet, J. M., Montal, R., Sia, D. & Finn, R. S. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 15, 599–616 (2018).
2. EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 69, 182–236 (2018).
3. Zhu, A. X., Kang, Y., Yen, C., Finn, R. S., Galle, P. R., Llovet, J. M. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2045, 1–15 (2019).
4. Mizejewski, G. J. Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy. Expert Rev. Anticancer Ther. 2, 709–735 (2002).
5. Villanueva, A., Portela, A., Sayols, S., Battiston, C., Hoshida, Y., Méndez-González, J. et al. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology. 61, 1945–1956 (2015).
Cited by
66 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献